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ABSTRACT
The Effect of 5-Aminolevulinic Acid Based Photodynamic 
Therapy and Photochemical Internalization of 
Bleomycin on the F98 rat glioma cell line
by
Khishigzaya Kharkhuu
Dr. Steen J. Madsen, Examination Committee Chair 
Chair, Department o f  Health Physics 
Associate Professor o f  Health Physics 
University o f Nevada, Las Vegas
The F98 rat glioma cell line, a model for human malignant glioma, was used to 
investigate the efficacy o f 5-aminolevulinic acid (ALA)-mediated photodynamic therapy 
(PDT) under varying light irradiation conditions. Cells in monolayer were pre-incubated 
in ALA for 4 hours prior to 635 nm light exposure. Using clonogenic survival assays, it 
was found that F98 glioma cells were sensitive to ALA-PDT; survival was inversely 
proportional to light fluence. As evidenced from the LD 5 0  (4 J cm'^ at a fluence rate o f  35 
mW  cm'^), ALA-PDT was found to be more effective in F98 cells compared to that found 
in another commonly used rat glioma cell line (BT4 C). In contrast to findings in BT4 C 
cells, F98 survival was independent o f fluence rate.
ALA-PDT was tested for its ability to enhance the cytotoxicity o f Bleomycin (BLM), 
a procedure termed photochemical internalization (PCI). F98 cells were incubated in 
ALA and BLM prior to illumination. In all cases, no difference in survival was observed
111
between F98 cells subjected to ALA-PCI delivery o f BLM and cells treated with 
ALA-PDT. These findings suggest that ALA is not an ideal compound for PCI 
applications.
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CHAPTER 1
INTRODUCTION 
I . I Glioblastoma M ultiforme 
Glioblastoma multiforme (GBM) is a high grade glioma and is one o f  the most highly 
malignant, aggressive and difficult to treat tumors. It is the most frequent primary brain 
tumor in adults accounting for approximately I % o f all cancer deaths (Madsen and 
Hirschberg 2006). The prognosis o f patients with these tumors is poor, and traditional 
therapies, such as surgical tumor resection followed by external beam radiation and/or 
chemotherapy, have done little to alter the fatal outcome o f this disease. No significant 
advancements in the treatment o f GBM have occurred in the past three decades. Although 
current therapies remain palliative, they have been shown to increase progression-free 
survival. From the time o f diagnosis, the mean survival time is approximately 17 weeks 
without treatment (Rao 2003). M ean survival is inversely correlated with age. Patients 
treated with optimal therapy, including surgical resection, radiation therapy, and 
chemotherapy, have a median survival o f  approximately 9 to 12 months, with 2-year 
survival rates in the range o f only 8  to 12% (Stupp et al. 2002). The 5-year survival rate 
o f the disease has remained unchanged over the past 30 years, and stands at less than 5 % 
(M cLendon and Halperin 2003).
GBMs present with an irregular, content enhancement pattern on Computed 
Tomography (CT) and Magnetic Resonance Imaging (MRI) scans. They tend to have a 
hemorrhagic component and are characterized histologically by the presence o f vascular 
endothelial proliferation and wide areas o f necrosis. Consistent with these areas o f 
necrosis from astrocyte cell death, is significant disruption o f the blood-brain barrier 
(Rao 2003).
Treatment failure is due to the presence o f subpopulations o f  highly invasive cells 
that disseminate into the surrounding brain parenchyma and result in tumor recurrence at 
the edges o f the resection cavity and/or at distant sites in the brain (Loustau et al. 2004).
Surgery and radiotherapy are the mainstay o f GBM  treatments. Surgery is an 
important first step in the treatment o f  GBM. However, it is extremely difficult to remove 
all tumor tissue without causing severe damage to normal brain. Surgical studies have 
concluded that complete resection o f the tumor is observed in less than 2 0  % o f patients, 
and is primarily due to difficulties involving indistinct tum or boundaries (Stummer et al. 
2006). Conventional radiotherapy can prolong survival, but it cannot cure GBM  - the 
tolerance o f healthy brain being lower than the dose required for tumor control. 
Chemotherapy is also not very effective, probably because most cytotoxic agents cannot 
penetrate the blood-brain barrier in sufficient amounts. All-in-all, there is an urgent need 
to find new therapies for this extremely aggressive disease. In particular, much effort has 
been directed towards the development o f localized therapies with the goal o f eradicating 
infiltrating glioma cells in the resection margin.
1.2 Photodynamic Therapy
Photodynamic therapy (PDT) is an emerging modality for the treatment o f neoplastic 
and non-neoplastic diseases. It is a local form o f treatment that involves the 
administration o f a tumor-localizing photosensitizing drug followed by photoactivation. 
This therapy results in a series o f photochemical and photobiological events that cause 
irreversible photo-damage to tumor tissues. It is based on the concept that certain 
photosensitizers preferentially accumulate in tum or tissue followed by activation o f 
appropriate wavelengths o f light to generate active molecular species, such as free 
radicals (especially singlet molecular oxygen) that are toxic to cells. Because o f the 
tumor-specific photosensitizer accumulation and the carefully directed light application, 
PDT represents a more selective method o f tum or treatment than chemo- or radiation 
therapies.
The basic principles o f PDT are illustrated in Fig. 1. Upon absorption o f light, a 
photosensitizer molecule is excited to a short-lived singlet state. Following excitation, 
the sensitizer looses its energy by a variety o f competing pathways. From the singlet state 
the sensitizer can readily decay back to its ground state and emit energy in the form o f 
fluorescence. Alternatively, it can convert, by intersystem crossing, to the more stable 
triplet excited state. In this metastable triplet state, the sensitizer can decay to its ground 
state by emission o f  longer lived phosphorescence or, because o f  its relatively long 
lifetime (100 ps), it can interact with the local environment, i.e. tum or tissue, via a type I 
and or type II reaction mechanism that initiates biochemical reactions (Ochsner 1997).
Singlet
excited
state
Triplet
excited
state
Fluoroscence
Phosphorosoem
PS Ground state
Fig. I. Photochemical reactions o f the excited photosensitizer (PS)
Type I photochemistry involves direct electron transfer between the triplet sensitizer 
and a nearby substrate to create radicals that further react with oxygen. This reaction will 
result in peroxyl radicals which will undergo typical radical chain reactions (Calzavara- 
Pinton 2007). Type II photochemistry involves energy transfer from the excited triplet 
state o f the sensitizer to ground state molecular oxygen resulting in the production o f 
singlet oxygen -  a highly reactive form o f oxygen. Singlet oxygen is a very powerful 
oxidizing agent that can oxidize many different biomolecules resulting in damage to a 
variety o f cellular structures. Due to its extremely short lifetime (less than 0.04 ps in 
biological tissue) and, accordingly, a short range o f action ( 1 0 - 2 0  nm) inside the cell, the 
activity o f  singlet oxygen is restricted to its point o f production making the photodamage 
high ly  loca lized  (D olm ans et al. 2003).
The photophysics o f PDT dictate that it is a light and oxygen catalyzed process with 
no toxicity in the absence o f  oxygen, and photosensitizing drugs are inactive until
illuminated. In summary, PDT efficacy depends on the availability o f photosensitizer, 
light and oxygen.
The importance o f  tissue oxygenation in PDT has been demonstrated by several 
researchers (See et al. 1984; Henderson et al. 1987). The level o f tissue oxygenation must 
be adequate to sustain singlet oxygen formation. Hypoxic cells, those with less than 5 % 
oxygenation, have been found to be resistant to PDT (M acdonald and Dougherty 2001). 
Henderson et al. (1987) have reported that oxygen consumption depends on the fluence 
rate o f  light, and that tissue destruction might be enhanced by using lower fluence rates. 
Lower fluence rates do not deplete the tissue’s oxygen supply as rapidly and, as a result, 
the tissue is exposed to greater concentrations o f  singlet oxygen for a longer time during 
treatment.
W hile an ample oxygen supply is necessary during PDT treatment, eventual 
destruction o f  the tum or microvasculature is also crucial to starve tum or cells o f  oxygen 
and nutrients since gliomas are known to progress by inducing angiogenesis. Sitnik et al. 
(1998) have suggested that fluence rates can be judiciously chosen to maximize exposure 
to singlet oxygen during treatment, while the total fluence can be adjusted to ensure that 
the tumor microvasculature eventually collapses, starving the tum or o f oxygen and 
nutrients.
The optimal light fluence used to activate a photosensitizer in human cancers is 
unknown. Light fluence is expressed in J cm'^, but the PDT dose depends on the 
spectrum o f the light source, irradiation geometry, depth o f penetration, light scattering in 
the tissue, concentration o f  the photosensitizer in the tissue, hemorrhage within the tumor.
ambient oxygen concentration and other factors. This makes the PDT dose difficult to 
calculate (W ebber et al. 2000).
The most commonly used photosensitizers for brain tum or therapy are Photofrin® 
and hematoporphyrin derivative. However, these sensitizers have the disadvantage o f 
causing prolonged skin sensitization. Perhaps more importantly, damage to normal brain 
tissue has been reported in preclinical studies (Ito et al. 2004). There are a number o f 
second-generation photosenitizers and prodrugs under preclinical development. For 
example, 5-aminolevulinic acid (ALA) has been successfully used to diagnose and treat 
neoplastic tissue (Tsai et al. 2004). ALA itself is not a photosensitizer and serves as the 
naturally occurring biological precursor for protoporphyrin IX (PpIX), a photosensitizer, 
in heme biosynthesis (Fig. 2). Heme synthesis is regulated by negative feedback control 
on ALA production. W hen ALA is administered exogenously, this inhibitory control can 
be bypassed and enzyme ferrochelatase (an enzyme that incorporates iron into PpIX in 
heme synthesis) activity becomes rate-limiting enabling the accumulation o f PpIX in 
cells which renders them photosensitive (Solban et al. 2006).
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Fig. 2. Heme biosynthetic pathway
ALA-induced PpIX has been shown to selectively accumulate in a number o f 
neoplastic tissues, which is probably due to altered activity levels o f the enzymes o f the 
heme biosynthetic pathway within transformed cells (Leunig et al. 2000). For example, 
uroporphyrinogen has been reported to be higher in some tumors, whereas ferrochelatase 
is often lower (Peng et al. 1997). The preferential accumulation o f  ALA in tumors has 
obvious clinical relevance since it results in selective destruction o f  neoplastic tissues.
Natural PpIX from ALA is formed within the mitochondria o f target cells. 
M itochondria occupy 15-50%  o f the total cytoplasmic volume o f most animal cells, and 
participate in more metabolic functions than any other organelle (Chakrabarti et al. 1998): 
their proper function is essential to maintain normal cellular metabolism. M itochondria 
have been implicated as an important target for PDT and their damage has been shown to 
directly correlate with cell death, in particular, apoptosis (Dougherty et al. 1998).
The fluorescence-guided resection o f glioblastoma multiforme by ALA -induced 
PpIX has been investigated in a number o f clinical studies and the results suggest a role 
for PDT as a therapeutic modality (Stummer et al. 2000). ALA-induced PpIX has several
light absorption maxima, from the largest peak in the Soret band at about 405 nm, to 
smaller peaks in the Q-bands at approximately 510, 545, 580 and 630 nm. From a clinical 
viewpoint, photosensitizers with absorption spectra in the 650 -  800 nm  regions are 
preferred since they allow deeper light penetration in tissue (Calzavara-Pinton et al. 
2006).
A num ber o f studies examining the utility o f ALA in various brain tum or models 
have been performed in the past several years (Friesen et al. 2002). The combination of 
excellent tumor-to-normal brain tissue localization (Angell-Petersen et al. 2006; Lilge et 
al. 1998) short period o f skin photosensitization (24-48 h) (Kennedy and Pettier 1992) 
and the possibility o f oral administration makes ALA a promising photosensitizer for use 
in fractionated or repeated PDT treatments o f GBM patients.
1.3 Photochemical Internalization
Photochemical internalization (PCI) is a novel technology which may improve the 
therapeutic effect o f macromolecules and other compounds that accumulate in endocytic 
vesicles (Berg et al. 2005). M olecules trapped in endocytic vesicles are inactive. PCI is 
based on the photodynamic effect which is used to rupture the vesicular membranes o f 
endosomes so that endocytosed intact macromolecules can be released into the cytosol 
where they may exert their therapeutic effects instead o f being degraded by lysosomal 
hydrolases. The concept (illustrated in Fig. 3) is based on the use o f specially designed 
photosensitizers, which localize preferentially in the membranes o f endocytic vesicles. 
Upon exposure to light o f appropriate wavelengths (usually red light), the photosensitizer 
induces the formation o f reactive oxygen species (e.g. singlet oxygen) which cause
photooxidation o f the endocytic membranes and subsequent release o f  encapsulated 
macromolecules. The PCI-based relocation and activation o f the macromolecules has the 
advantage o f  minimal side effects since the effect is localized to the area exposed to light. 
The endosomal escape o f macromolecules including genes, oligonucleotides and proteins 
by means o f PCI has been documented both in vitro and in vivo and has been shown to 
increase the therapeutic effect in a synergistic manner (Berg et al. 2005).
Fig. 3. Transport o f molecules to the cytosol by PCI. The photosensitizer (S) and the 
selected molecule (M) are endocytosed by the cells (I, illustrates the invagination o f  the 
plasma membrane) and both compounds end up in the same vesicles (II). W hen these 
vesicles are exposed to light, the membranes o f these vesicles will be ruptured and the 
contents released (III) (Berg et al., 2005).
Photosensitizers used in PCI should fulfill certain criteria, perhaps most importantly, 
they should localize in the endocytic compartments (Hogset et al. 2003). According to 
Gaullier et al. (1995) PpIX was found to sublocalize to lysosomal compartments in 
human kératinocytes after long term incubation (42h) with ALA. Thus, ALA-PDT may 
have the potential to damage endocytic vesicles releasing their contents under certain 
conditions (Selbo et al. 2001). ALA-based PCI o f the immunotoxin M O C3I-gelonin has 
been shown to cause significant cytotoxic effects in W iDr cells (a colon adenocarcinoma
cell line) (Selbo et al. 2001). This is an important observation and provides the rationale 
for the proposed work in rat glioma cell lines -  the PCI effect has not been investigated in 
brain tumor cell lines. O f particular interest is the ability o f  ALA-based PCI to enhance 
the effects o f chemotherapeutic agents such as bleomycin (BLM) for the treatment o f 
malignant gliomas. This is an important consideration since chemotherapeutic agents 
have been relatively ineffective in the treatment o f  brain tumors.
1.4 Bleomycin
Bleomycin (BLM) is a water soluble glycopeptidic antibiotic used in anticancer 
chemotherapy and is given as a treatment for several types o f cancers including head- 
and-neck, malignant lymphomas and testicular carcinomas. BLM possesses very high 
intrinsic cytotoxicity and acts by causing DNA strand breaks. Indeed, as few as 500 BLM 
molecules introduced into the cytosol are sufficient to kill many cell types (Pron et al. 
1999). However, it is known that the BLM effect is limited by its inability to cross the 
plasma membrane due to its relatively large size (molecular weight o f 1.5 kDa) and 
hydrophilic characteristic. The transport mechanism o f BLM  into cells has been the focus 
o f several studies. Using radiolabeled BLM, Pron et al. (1993) found an association 
between receptor proteins on the plasma membrane and the uptake o f BLM, suggesting it 
is taken up by cells through a receptor-mediated endocytotic mechanism. The observation 
that BLM appears incapable o f escaping from endocytic vesicles explains the 
development o f a variety o f  techniques to permeabilize the barrier membrane, including 
well known electroporation techniques. Utilizing specifically localized photosensitizers 
and light to rupture vesicle membranes is a promising approach for exploiting the
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therapeutic potential o f BLM. In vitro PCI studies with BLM have shown that 
photochemical treatment can substantially enhance the biological effect o f this agent in 
W iDr colon adenocarcinoma and V79 lung fibroblast cell lines. (Hogset et al. 2003; Berg 
et al. 2005).
BLM is known as a cell cycle specific chemotherapeutic agent as it mainly affects 
dividing cells. The fact that healthy neurons and normal glial cells do not divide, or 
possess extremely low division rates makes BLM advantageous in clinical use o f  brain 
cancer therapy since cancer cells are characterized by its high cell division (Leif et al. 
1993). The primary motivation for using this chemotherapeutic agent is that it has been 
used in a number o f PCI studies which can serve as benchmarks against which the results 
o f  the present work can be compared.
1.5 The F98 Rat Glioma Cell Line
The F98 rat glioma cell line used in this study was originally established by Dr s. A. 
Koestner and W. W echsler at Ohio State University. It is chemically induced in CDF 
(Fischer) rats by the i.v. administration o f a single dose o f N-ethyl-N-nitrosourea (ENU, 
50mg kg b.w.) on the 20* day o f gestation (Barth 1998). N itrosourea-induced 
malignant cell lines reliably produce rapidly growing tumors. The techniques involved 
are relatively simple, cheap and in vitro, in vivo studies can be carried out in parallel 
(Whittle et al. 1998). The biological characteristics o f this tumor closely resemble those 
o f human glioblastoma. The transplantable tum or displays an infiltrative pattern o f 
growth within the brain and is weakly immunogenic in syngeneic rats (Barth 1998). 
Knowledge o f the immunogenicity o f a tum or model is an important factor for
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determining its appropriateness in therapeutic studies where survival is the end point. For 
example, certain immunogenic glioma cell lines, like C6 and 9L are not suitable for 
studies in immunocompetent rats if  the objective is to prolong and register animal 
survival (Fournier et al. 2003). F98 cells have been found to be resistant to a variety o f 
treatment modalities including chemo-, radio-, and immunotherapy and, to this date, only 
25% o f tumor-bearing animals have been cured using these standard therapeutic regimens 
(Barth et al. 2003). The failure o f  cancer treatments for human gliomas is mainly 
attributed to its highly invasive nature. F98 cells are highly invasive and, as such, are 
highly suitable for studying human glioma resistance (Sibenaller et al. 2005).
1.6 Thesis Objectives
The overall objective o f  this thesis is to determine the efficacy o f ALA-mediated PDT 
and PCI in an F98 rat glioma cell line. The work consists o f three specific aims. ALA 
dark toxicity and PpIX fluorescence yields will be investigated in specific aim #1. It is 
hypothesized that ALA toxicity and PpIX fluorescence yields in F98 cells are similar to 
those observed in other rat glioma cell lines.
In specific aim #2, the effects o f  light fluence and fluence rate in the rat glioma cell 
line will be determined. There are numerous studies suggesting that low fluence rates 
result in more damage than high fluence rates for the same total fluence. It is very 
important to elucidate the different fluence rate effects in photodynamic therapy for 
effective treatment planning. As has been found in other rat glioma cell lines, it is 
hypothesized that higher light fluences and lower fluence rates are more effective at 
killing glioma cells.
12
In specific aim #3, the ability o f ALA-PCI to enhance the effects o f BLM  in the F98 
rat glioma cell line will be investigated. It is hypothesized that ALA-PCI with BLM will 
have a greater cytotoxic effect than that achievable with ALA-PDT or BLM alone.
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CHAPTER 2
MATERIALS AND METHODS
2.1 Chemicals
D ulbecco’s modified Eagle medium (DMEM), Phosphate Buffered Saline (PBS), and 
trypsin-EDTA were purchased from Invitrogen Corp., Carlsbad, CA. 5-Aminolaevulinic 
acid (5-ALA) and bleomycin in powder form (15 lU  per vial) were purchased from 
Sigma (St.Louis, MO).
2.2 Cell Culture
The F98 cells used in all experiments were provided by Dr. Chung-Ho Sun from the 
University o f California, Irvine. Originally, the F98 cell line was established from 
gliomas induced in CDF (Fischer) rats by the i.v. administration o f a single dose o f  N- 
ethyl-N-nitrosourea (ENU, 50 mg kg ' b.w.) on the 20* day o f gestation. Cells were 
routinely cultured in monolayer in Dulbecco’s modified Eagle medium (DMEM), 
supplemented with 10% fetal bovine serum (FBS), 50 mM  HEPES buffer (pH 7.4), 
penicillin (100 U m f ')  and streptomycin (100 mg m f ') . They were incubated in a 
humidified chamber with 5% CO 2 at 37°C. For routine maintenance, cells were 
subcultured at 80-90%  confluence. Proliferating cells received fresh medium every third 
day. F98 cells were seeded in the medium at a density o f  about 150*10^ cells per 25 cm''
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cell culture flasks, and incubated for 48 hours prior to each experiment. Prior to drug 
treatment and irradiation, cells were switched to a serum-free medium (0% FBS) since 
serum can act as an extracellular competitor for PpIX (Flanania et al. 1992).
2.3 PpIX Fluorescence 
In one set o f experiments, F98 cells were incubated in ALA and a serum-free medium 
for 4 h. PpIX fluorescence intensity was evaluated for ALA concentrations ranging from 
0 to 4 mM using a FACS Calibur cytometer. In another set o f  experiments, cells were 
incubated in 1 mM ALA for times ranging from 1 to 24 h and PpIX fluorescence 
intensity was evaluated using the cytometer.
2.4 ALA Toxicity
F98 cells were incubated in the dark for 4 h with 1 , 6 ,  12, 18 or 24 mM ALA in a 
serum-free medium. Exposure to light was avoided during incubation with ALA. 
Following incubation, cells were harvested, counted and prepared for colony growth as 
described in section 2.5.
2.5 Photodynamic Therapy 
F98 cells were seeded in the medium at a density o f about 150 %10  ̂ cells per 25 cm^ 
cell culture flasks. After 48 h, cells were washed with 5 ml PBS and 5 ml o f  serum-free 
DMEM was added. 100 mM ALA stock was prepared immediately before treatment with 
100 mM HEPES buffer and pH adjusted to 7.3 - 7.6 using 10 M NaOH. 50 pi o f  the 100 
mM ALA stock was added to the cells in 5 ml serum-free medium to a final
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concentration o f 1 mM and incubated for 4 h. The serum-free medium (without ALA) 
was also used for the control group. Cells were assigned into three groups: group 1, 
control -  no ALA; group 2, dark control -  ALA only; and group 3, ALA-PDT. After 
incubation, cells incubated with 1 mM ALA for 4 h (except the dark controls) were 
subjected to light fluences o f 2, 4, 10 or 20 J cm  ̂delivered at fluence rates o f 5, 25, or 40 
mW cm .̂ All illuminations were performed using a 400 pm  core diameter optical fiber 
(with microlens) coupled to a diode laser (High Power Devices, North Brunswick, NJ) 
emitting light at a wavelength o f 635 nm. Power output at the tip o f the fiber was checked 
with a power meter. The beam was expanded to a spot size o f  37.5 mm radius in order to 
cover the monolayer cell culture homogeneously. Immediately after irradiation, cells 
were washed in PBS, harvested using trypsin, and resuspended in drug-free culture 
medium. Cells were counted using a Coulter Counter and plated at various densities in 
culture dishes and further incubated with the complete medium for colony formation. All 
experiments, in which cells were exposed to ALA, were carried out in subdued light. Cell 
survivals were evaluated using a colony formation assay. The clonogenic assay was 
performed to assess the proliferation ability after ALA-PDT.
2.6 Bleomycin Toxicity 
BLM powder was dissolved in PBS and further diluted to achieve the desired 
concentrations. F98 cells were incubated in varying concentrations (0.1 -  10 pg m f ')  o f 
BLM and serum-free medium for 4 h. Following incubation, cells were washed, 
trypsinized, counted and prepared for colony growth as described in section 2.5.
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2.7 ALA-Based PCI o f Bleomycin 
F98 cells were subjected to varying incubation times in ALA and BLM prior to 
illumination. In the initial set o f  experiments, F98 cells were coincubated with 1 mM 
ALA and 0.1 pg ml * BLM in serum-free medium for 4 or 18 h. In later experiments F98 
cells were first incubated in ALA for 18 h followed by 4 h incubation in 0.1 pg m f ' BLM. 
Following incubation, cells were irradiated with 635 nm light (fluence rate = 5 mWcm'^, 
fluence = 2 J cm^). Subsequent to inadiation, cells were harvested and prepared for 
colony growth as described in section 2.5. In addition to the control (no ALA, no light), 
two dark control groups (ALA only, 4 and 18 h) and a BLM  + light group were evaluated. 
All experiments were carried out in subdued light.
2.8 Colony Formation Assay 
All F98 cultures were incubated in the dark for 7 -  9 days after the experiments until 
visible colonies were observed. Thereafter, cells were stained with crystal violet, and 
surviving colonies counted manually. Colonies containing more than 50 cells were 
counted. The number o f colonies was expressed as a fraction o f the dark control (ALA 
only).
Survival was determined by:
number o f colonies from treated cells/ number o f treated cells seeded
number o f colonies from dark control cells/ number o f dark control cells seeded
• X 1 0 0
For all measurements, triplicate plates were used for each point and each experiment 
was carried out more than three times. In all cases, data are presented as mean ± SD.
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CHAPTER 3
RESULTS
3.1 PpIX Fluorescence and ALA Toxicity 
The data in Fig. 4 show that PpIX fluorescence in F98 cells increases as a function o f 
ALA incubation time. After 18 h, the fluorescence signal reached a plateau suggesting 
that the maximum PpIX accumulation had been attained in this cell line. As illustrated in 
Fig. 5, PpIX fluorescence reached a plateau at an ALA concentration o f approximately 2 
mM. ALA toxicity was investigated by evaluating the survival o f F98 cells after 
incubation for 4 h with increasing concentrations o f ALA (Fig. 6). At concentrations up 
to 12 mM no significant decrease in cell viability was observed. However, significant 
dark toxicity was seen in cells incubated at higher concentrations. Surviving fractions 
markedly diminished to about 24 % and 11 % at concentrations o f 18 and 24 mM  
respectively.
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Time (h)
Fig. 4. Time dependent PpIX fluorescence formation in F98 cells. Cells were incubated in 
1 mM ALA for different times. Each data point represents the mean (±SE) o f 2 
experimental trials.
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Fig. 5. Dose dependent PpIX fluorescence formation in F98 cells. Cells were incubated in 
different concentrations o f ALA for 4 h. Each data point represents the mean (±SE) o f 2 
experimental trials.
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Fig. 6. F98 cell survival as a function o f ALA concentration. In all cases, cells were 
incubated in ALA and serum free medium for 4 h. Each data point represents the mean 
(±SE) o f more than 3 experimental trials.
3.2 Photodynamic Effects on F98 Cells 
Fig. 7 illustrates the survival o f F98 cells after 4 h incubation in 1 mM  ALA and 
exposure to 635 nm light delivered at a range o f  fluences and fluence rates. In each case, 
cellular viability was estimated by normalizing the results o f the colony formation assay 
to cells that were exposed to ALA-only (dark control). Control experiments were 
performed to insure the reduction in cell viability during PDF was caused solely by 
photosensitized PDF reactions. A fluence-dependent decrease in cell viability was clearly 
observed at all three light fluence rates investigated. Neither sole incubation with 1 mM  
ALA, nor the laser light alone, had a significant effect on cell viability. Significant 
reduction o f  cell viability, relative to dark control, was observed when irradiating with 4, 
10, or 20 J cm ^ at all fluence rates investigated. At 2 J cm ^, however, low or no 
significant phototoxicity was observed when compared with dark control and the mean 
percent survivals were 95.7 ± 8.2%, 86.8 ± 12.1% and 94.4 ± 13.2% for fluence rates o f
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5, 25 and 40 mW  cm'^ respectively. A t 4 J cm'^, the cell killing reached approximately 
half the value o f non-irradiated controls (53.2 ± 8.3%, 49.3 ± 15.7%, and 42 ± 6.46% for 
fluence rates o f  5, 25 and 40 mW  cm ^ respectively). After exposure to 10 J cm ^ cell 
survival decreased to 23.4 ± 4.9%, 18.8 ± 3.1% and 29.7 ± 9% for fluence rates o f 5, 25 
and 40 mW  cm ^ respectively. Exposures to 20 J cm"  ̂ resulted in close to complete cell 
inactivation at all fluence rates investigated (5.7 ± 1.2%, 1.8 ± 0.3% and 6.4 ± 0.6% for 
fluence rates o f 5, 25 and 40 mW  cm'^ respectively). As illustrated in Fig. 7, there do not 
appear to be significant differences in survival for the three fluence rates investigated.
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Fig. 7. Fluence and fluence rate effect o f ALA-PDT in F98 cells. Cells were incubated 
with 1 mM ALA for 4 h prior to treatment. Each data point represents the mean (±SE) o f 
more than 3 trials.
3.3 B leom ycin  T oxicity  
The BLM  dose response curve was generated for the F98 cell line following 4 h 
treatment with increasing concentrations o f BLM  (Fig. 8). Initial toxicity evaluation was 
carried out for BLM  concentrations ranging from 1 to 60 pg ml ’. For this range, colony
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counts rapidly diminished. At concentrations above 10 pg ml ’ the toxicity was so high 
that the percent survival became negligible. The results presented in Fig. 8 show that F98 
glioma cells are very sensitive to B L M - the LD 50  is approximately 0.25 pg ml ’.
BLM Concentration (iig/ml)
Fig. 8. F98 cell survival as a function o f  BLM  concentration. In all cases, cells were 
incubated in BLM and serum free media for 4 h. Each data point represents the mean 
(±SE) o f  more than 3 experimental trials.
3.4 Photochemical Internalization 
The effects o f ALA-PCI are illustrated in Figs. 9 and 10. In the case o f  ALA and 
BLM co-incubation (Fig. 9) the data show that there was no statistically significant 
difference (95% confidence interval) in survival between cells subjected to PDT and 
those treated with PCI for both incubation times investigated (4 and 18 h). Not 
surprisingly, PDT was more effective in the 18 hour ALA-incubated cells: 95 ± 8 % and 
40 ± 7 % for PDT after 4 and 18 hour ALA incubation respectively. No difference in 
survival was observed between BLM-only cells and BLM -only cells exposed to light 
suggesting that bleomycin does not have a photosensitizing effect (data not shown). As
22
illustrated in Fig. 10, changing the incubation conditions (18 h ALA followed by 4 h 
BLM) did not result in a statistically significant difference in survival between the PDT 
and PCI groups.
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Fig. 9. ALA based PCI o f BLM in F98 cells after 4 and 18 h co-incubation with 
1 mM ALA and 0.1 pg ml ' BLM  prior to light exposure (2 J cm'^). Each data point 
represents the mean (±SE) o f more than 3 trials.
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Fig. 10. ALA based PCI o f  BLM in F98 cells after 18 h -  1 mM  ALA followed by 4 h -  
0.1 pg ml * BLM incubation prior to light exposure (0.5 J cm ^). Each data point 
represents the mean (±SE) o f 2 trials.
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CHAPTER 4 
DISCUSSION
At present, glioblastoma multiforme is considered an incurable disease. Results have 
been poor with conventional treatments involving surgery followed by adjuvant 
radiotherapy and chemotherapy. Because o f the failure to control local recurrences with 
conventional therapies, other methods are currently being developed (Sandeman 1986). 
PDT is an appealing treatment option for GBM patients due to its selective ability to 
target brain tum or cells. First generation photosensitizers, such as hematoporphyrin 
derivatives, are not ideally suited for PDT due to lack o f  tumor selectivity and 
complications associated with cutaneous photosensitivity (Dougherty et al. 1990). Thus, 
new photosensitizers and prodrugs (including ALA) are under active investigation to 
evaluate their efficacy for PDT o f malignant gliomas. ALA is a naturally occurring 
metabolite in the heme synthetic pathway and a precursor o f PpIX, a potent 
photosensitizer. ALA has been shown to have fewer side effects and a much more 
transient phototoxicity compared to first generation compounds (Rick et al. 1997).
In the present study, the utility o f ALA was assessed in the PDT treatment o f weakly 
immunogenic F98 glioma cells in vitro. Since some cells are not readily photosensitized 
when exposed to exogenous ALA, it is advisable to perform in vitro studies in tum or cell 
lines prior to the initiation o f animal studies (Betz et al. 2002). W hetsell et al. (1978) and
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Percy et al. (1981) have shown that neurons, glial cells and Schwann cells in culture 
synthesize porphyrins from ALA.
The results illustrated in Figs. 4 and 5 show that F98 glioma cells are readily capable 
o f synthesizing PpIX following ALA exposure. The trend o f increasing PpIX 
fluorescence intensity as a function o f ALA incubation time (Fig. 4) has also been 
observed in other cell lines (Gamarra et al. 2002) including the BT 4 C rat glioma line 
(Ziegler 2007). In F98 cells, a fluorescence plateau was reached after approximately 18 h 
o f ALA incubation indicative o f feedback inhibition o f porphyrin synthesis (Stummer et 
al. 1998). The results illustrated in Fig. 5 show that PpIX fluorescence saturates at an 
ALA concentration o f approximately 2 mM which is in good agreement with the findings 
o f Ziegler (2007) in a BT 4 C rat glioma cell line. The observation o f a plateau is o f 
particular importance, because it predicts that any given increase in ALA dose will not 
inevitably increase the availability o f ALA-induced porphyrins. On the other hand, 
unwanted side-effects related to ALA may be more liable to occur if  ALA doses in 
patients are increased capriciously (Stummer et al., 1998).
It has been shown that ALA can induce cytotoxicity in the absence o f  light -  the so- 
called dark toxicity which is due to the generation o f reactive oxygen species via ALA 
oxidation (Xing et al. 2001). In the F98 cell line, a significant reduction in survival was 
observed at ALA concentrations exceeding 12 mM  (Fig. 6 ). Based on this data, the L D 50  
would appear to be in the range o f  12 to 18 mM. These results are in general agreement 
with the findings in BT 4 C rat glioma cells where the L D 5 0  was estimated at 24 mM 
(Madsen et al. 2006). The results are also consistent with the dark toxicity observed in a 
W af human bladder carcinoma cell line which demonstrated no decrease in survival at
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ALA concentrations less than 10 mM (Bachor et al. 1996). Thereafter, survival dropped 
abruptly to 15 % at a concentration o f 15 mM.
Overall, the results presented in Figs. 4-6 provided guidance as to the optimal ALA 
concentration and incubation time to use for the PDT and PCI experiments. In all cases, a 
1 mM ALA concentration and a 4 h incubation time were chosen for the PDT studies and 
the initial PCI investigations.
The F98 glioma cell line was used as a model system in this study since these cells 
form rat brain tumors that mimic the fundamental characteristics o f human GBM 
including infiltrative growth and invasiveness. Furthermore, like human GBMs, F98- 
derived tumors have been shown to be refractory to a wide variety o f treatment 
modalities including standard therapeutic regimens consisting o f  radiation and 
chemotherapeutic agents (Barth et al. 2003).
Recently, much effort has been devoted to determining the optimal light dosimetry 
parameters for PDT. To that end, the response o f F98 glioma cells to various light 
fluences and irradiation conditions were investigated. Not surprisingly, a significant light 
fluence dependent PDT response was observed as measured by clonogenic survival: 
higher light doses resulted in reduced survival. As illustrated in Fig. 7, exposure to light 
doses o f 20 J cm ^ resulted in less than 10 % survival whereas 2 J cm‘̂  had little impact 
on cell viability. The results suggest that the F98 cell line is slightly more sensitive to 
ALA-PDT compared to BT 4 C cells. For example, at a fluence rate o f 35 mW  cm'^, the 
LD50 for BT 4 C and F98 cells occurred at light fluences o f  approximately 7 and 4 J cm ,̂ 
respectively (M adsen et al. 2006). The reasons for this slight discrepancy in ALA-PDT
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response among the two glioma eell lines are not known but may be due to differenees in: 
(1) cell metabolism, (2) photosensitizer binding, and/or (3) organelle concentration.
From the results presented in Fig. 9 it is hardly surprising that phototoxicity increased 
significantly following 18 h incubation. For example, a light fluence o f 2 J cm'^ resulted 
in surviving fractions o f approximately 95 and 40 % following 4 and 18 h incubation, 
respectively. The inereased PDT effieaey observed at longer ineubation times may be 
attributed to a number o f faetors ineluding an inerease in cellular PpIX eoncentrations. In 
addition, several investigators have deseribed the eritieal role o f intraeellular sensitizer 
loealization and distribution in cellular phototoxicity and PDT efficacy. Longer exposure 
to ALA may result in eombined targeting o f  several sites within the cell due to PpIX 
reloealization from mitoehondria to other organelles, including the plasma membrane 
(Lye Yee et al. 2002). Sueh PpIX reloeation is also likely to eause a shift from an 
apoptotic to a necrotic mode o f  cell death (Morgan and O seroff 2001).
As illustrated in Fig. 7, there was no signifieant difference in F98 survival as a 
function o f fluence rate. There have been numerous in vitro and in vivo studies 
investigating the impaet o f  fluence rate on PDT effieaey. In general, the deereased PDT 
efficacy observed at high fluence rates is attributed to rapid oxygen depletion and there is 
ample evidence to support this hypothesis in both multieellular 3-D spheroids (M adsen et 
al. 2000) and animals (Moor et al. 1997). During exposure to high fluence rates, oxygen 
depletion exeeeds replenishment and, as a result, the PDT effeet is limited only to eells in 
close proximity to the oxygen supply, i.e., cells in the outer spheroid layers or tum or eells 
in close proximity to the vasculature.
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Results o f fluence rate effects in monolayers have been mixed -  some studies have 
found a fluence rate dependence while others have failed to find such a relationship. The 
lack o f a fluence rate effect is hardly surprising since all cells in monolayers are well- 
oxygenated. In the present studies, it is hypothesized that oxygenation levels were 
sufficient to ensure survival o f F98 cells under all fluence rates investigated. It is 
interesting to note that, in a similar study employing BT4C rat glioma cells, a fluence rate 
effect was observed (Ziegler 2007): higher fluence rates resulted in increased survival. 
Differences in growth conditions and cell manipulation notwithstanding, the reasons for 
the discrepancy between the two cell lines is not understood at present and bears further 
investigation.
The biological activity o f a number o f chemotherapeutic agents is limited by their 
poor ability to enter the cytosol. BLM is a glycopeptidic antibiotic that binds to DNA 
causing single and double strand breaks. This agent has been used in a number o f 
standard cheomotherapeutic regimens for the treatment o f head and neck, esophagus and 
testicular carcinomas (Berg et al. 2005). Unfortunately, the clinical efficacy o f BLM is 
limited due to drug resistance and dose-dependent induction o f pulmonary fibrosis (Jani 
et al. 1992). Improvement in BLM  efficacy would allow for the delivery o f lower doses 
resulting in a concomitant decrease in morbidity.
BLM  enters the cytosol through the endocytic pathway. Poor escape from endocytic 
vesicles is a major barrier for delivery o f  the compound since it is unable to reach the 
cytosol where it can be transported to the nucleus. Instead, BLM  remains trapped in the 
endocytic vesicles and finally degraded in lysosomes. Thus, the development o f 
endosome-disruptive strategies, such as PCI, is o f great importance since they may
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enhance the clinical efficacy o f  BLM. The PCI technique, utilizing amphiphilic 
photosensitizers to enhance the activity o f  BLM, has been successfully documented by 
Berg et al. (2005) on two different carcinoma cell lines. The central question addressed in 
this study was whether BLM efficacy could be enhanced by ALA-PCI in a rat glioma cell 
line. The results presented in Figs. 9 and 10 suggest that ALA-PCI was not an effective 
delivery technique for the selected conditions investigated. In all cases, no significant 
differences in survival were observed between cells exposed to PDT and those subjected 
to PCI.
PCI efficacy is critically dependent on incubation time. In Fig. 9 two incubation 
times o f 4 and 18 h were considered based on the work o f Selbo et al. (2001) who 
investigated ALA-PCI efficacy in the W iDr -  colon adenocarcinoma cell line. These 
investigators used fluorescence microscopy which showed significant ALA-induced 
PpIX translocation as a function o f  incubation time. Not surprisingly, at short incubation 
times (a few hours), PpIX fluorescence was confined primarily to the mitochondria. At 
approximately 4 h, a small increase in PpIX fluorescence intensity was noted in the 
plasma membrane. At longer incubation times (> 24 h) a sharp increase in fluorescence 
intensity was observed in the cytoplasm suggesting PpIX localization to extra 
mitochondrial sites and indicative o f an endosome/lysosome association. Taken together, 
the fluorescence studies suggest that a PCI effect should be possible using a 4 h 
incubation time and that the effect is optimal after 24 h.
In both cases considered in Fig. 9, cells were co-incubated in ALA and BLM. This 
protocol can be problematic if  BLM -forming vesicles detach from the plasma membrane 
prior to sufficient incorporation o f PpIX. To minimize the risk o f this occurrence, a series
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o f experiments were performed in which F98 cells were first incubated in ALA for 18 h, 
followed by 4 h BLM incubation. Unfortunately, the results illustrated in Fig. 10, 
demonstrate an absence o f the PCI effect under these incubation conditions. The lack o f 
an observed PCI effect in the present work is likely due to limitations associated with the 
choice o f pro-drug (ALA). Optimization o f the PCI effect requires lipophilic sensitizers 
that localize in the plasma membrane. In that context, ALA would appear to be a sub- 
optimal choice since it is a hydrophilic molecule and its associated photosensitizer (PpIX) 
has strong mitochondrial affinity. It is also possible that the ALA-PpIX conversion 
kinetics in the F98 glioma cell line are different compared to those in other cell lines such 
as the W iDr line where ALA-PCI has been shown to have some effect (Selbo et al. 2001).
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CHAPTER 5 
CONCLUSION
PpIX fluorescence analysis in F98 rat glioma cells yielded results consistent with 
those observed in the B T 4 C rat glioma cell line. Data from the present study showed that 
maximum PpIX fluorescence was achieved following 18 h ALA incubation. In addition, 
it was found that the PpIX fluorescence intensity saturated at a relatively low ALA 
concentration o f 2 mM. This has significant clinical implications since it suggests that a 
therapeutic effect can be achieved at ALA concentrations well tolerated by patients. ALA 
dark toxicity was found to be similar to that observed in the BT 4 C cell line: the LD 5 0  was 
estimated to be between 12 and 18 mM in F98 glioma cells.
The present study demonstrated that ALA-PDT was very effective against F98 
glioma cells. As expected, higher light fluences resulted in reduced survival. The results 
suggest that the F98 cell line is more sensitive to ALA-PDT compared to BT 4 C cells. The 
LD 50  for F98 cells exposed to 35 mW  cm'^ occurred at a light fluence o f approximately 4 
J cm'^.
In contrast to the findings in BT 4 C cells, a fluence rate effect was not observed in the 
F98 cell line. The reasons for this discrepancy are not understood and require further 
investigation in more realistic oxygen-limiting conditions such as those found in multicell 
3-D spheroids and animal tumors.
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ALA-PCI was not an effective enhancer o f bleomycin efficacy in the F98 rat glioma 
cell line. The lack o f  an effect is likely due to the ineffectiveness o f  ALA in PCI 
applications. Future work will be aimed towards a better understanding o f  the PCI effect 
using more appropriate amphiphilic photosensitizers that preferentially localize in plasma 
membranes.
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